BioSpace News Archive

Bio-Path Holdings, Inc. announced that the Audit Committee of the Company’s Board of Directors approved the appointment of Ernst & Young LLP as the Company’s new independent registered public accounting firm, replacing former auditor, BDO USA, LLP.

Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax’’ or the ''Company’’), an outcome-driven connected healthcare company, today announced its wholly owned subsidiary Parallax Diagnostics, Inc. will execute a partnership strategy to develop, acquire or license monoclonal and polyclonal antibodies for the creation of a low cost and rapid screening test for COVID-19

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today provided an update on its clinical development programs for opaganib (Yeliva®, ABC294640)2

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received the final minutes from a meeting with the U.S. Food and Drug Administration (FDA) held on February 5, 2020.

Bristol Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the acceptance for presentation of its abstract of the results for Cohort 1 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations.

Pascal Biosciences Inc. has entered into a Term Sheet with SōRSE Technology to develop Pascal’s cannabinoid programs.

Neuromod Devices Limited (“Neuromod” or “The Company”), the Irish medical technology company specialising in non-invasive neuromodulation technologies, is pleased to announce that Mr. Florian Elsaesser has been appointed as Chief Commercial Officer.

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced a filing with the Respiratory Diseases Branch of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19).

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.